Wrote this IIT with @YJanjigianMD when I was a fellow and great to see this phase 2 study now completed. FOLFOX plus regorafenib and nivolumab for advanced EG cancer. ORR 76% and 6-month PFS 71%. Nice work @Sam_Cytryn and team! – at Manhattan, NY
NOW OF: A US single-arm, single-centre, ph 2 trial assesses the safety and activity of regorafenib in combination with nivolumab and chemotherapy in the first-line treatment of advanced oesophagogastric adenocarcinoma. #gicsmthelancet.com/journals/lanon…